ZA200202825B - Non-covalent inhibitors of urokinase and blood vessels formation. - Google Patents

Non-covalent inhibitors of urokinase and blood vessels formation.

Info

Publication number
ZA200202825B
ZA200202825B ZA200202825A ZA200202825A ZA200202825B ZA 200202825 B ZA200202825 B ZA 200202825B ZA 200202825 A ZA200202825 A ZA 200202825A ZA 200202825 A ZA200202825 A ZA 200202825A ZA 200202825 B ZA200202825 B ZA 200202825B
Authority
ZA
South Africa
Prior art keywords
urokinase
blood vessels
covalent inhibitors
activity
compounds
Prior art date
Application number
ZA200202825A
Other languages
English (en)
Inventor
Odile Esther Levy
Joseph Edward Semple
Michael I Weinhouse
Edwin L Madison
Amir P Tamiz
Original Assignee
Corvas Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvas Int Inc filed Critical Corvas Int Inc
Publication of ZA200202825B publication Critical patent/ZA200202825B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200202825A 2000-08-11 2002-04-10 Non-covalent inhibitors of urokinase and blood vessels formation. ZA200202825B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63748300A 2000-08-11 2000-08-11

Publications (1)

Publication Number Publication Date
ZA200202825B true ZA200202825B (en) 2003-07-10

Family

ID=24556134

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202825A ZA200202825B (en) 2000-08-11 2002-04-10 Non-covalent inhibitors of urokinase and blood vessels formation.

Country Status (8)

Country Link
US (1) US6586405B2 (es)
EP (2) EP1808440B1 (es)
KR (1) KR100879673B1 (es)
AT (2) ATE517910T1 (es)
DE (1) DE60034447T2 (es)
ES (1) ES2285989T3 (es)
IL (1) IL149042A (es)
ZA (1) ZA200202825B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7001887B2 (en) * 2001-02-02 2006-02-21 Chugai Seiyaku Kabushiki Kaisha Peptide derivatives
WO2002064140A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) * 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7262211B2 (en) * 2001-12-04 2007-08-28 Dendreon Corporation Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
DE50310038D1 (de) * 2002-03-11 2008-08-07 Curacyte Ag Hemmstoffe der urokinase, ihre herstellung und verwendung
US7019019B2 (en) * 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
DE602006009257D1 (de) 2005-06-24 2009-10-29 Wilex Ag Verwendung von urokinase-inhibitoren zur behandlunklerose (als)
DE102006050672A1 (de) * 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
CA2688346A1 (en) 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
US20100261662A1 (en) * 2009-04-09 2010-10-14 Endologix, Inc. Utilization of mural thrombus for local drug delivery into vascular tissue
DE102009022794A1 (de) * 2009-05-27 2010-12-02 Philipps-Universität Marburg Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel
US20110218517A1 (en) * 2009-10-09 2011-09-08 Ogle Matthew F In vivo chemical stabilization of vulnerable plaque
US8921319B2 (en) 2010-07-07 2014-12-30 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
JP2014516695A (ja) 2011-05-18 2014-07-17 バトリックス・メディカル・インコーポレイテッド 血管安定化用被覆バルーン
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
EP2960232A1 (en) * 2014-06-25 2015-12-30 DSM IP Assets B.V. Process for the production of a dipeptide derivative
US9777116B2 (en) 2014-10-16 2017-10-03 International Business Machines Corporation Porous/nanoporous PHT
CN109265370A (zh) * 2018-09-25 2019-01-25 四川什邡市三高生化实业有限公司 一种n-(9-芴甲氧羰基)-o-叔丁基-l-丝氨酸的制备方法
CN114502531A (zh) * 2019-07-08 2022-05-13 雷佐鲁特公司 制备血浆激肽释放酶抑制剂的方法
BR112022001054A2 (pt) * 2019-08-21 2022-03-15 Kalvista Pharmaceuticals Ltd Inibidores enzimáticos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675981B2 (en) 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
AU1025795A (en) * 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
CN1173872A (zh) * 1995-02-10 1998-02-18 巴斯福股份公司 凝血酶抑制剂
US6576613B1 (en) 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
JP4489976B2 (ja) * 1999-04-09 2010-06-23 ビーエーエスエフ ソシエタス・ヨーロピア 補体プロテアーゼの低分子インヒビター
DE10029014A1 (de) * 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10029015A1 (de) * 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa

Also Published As

Publication number Publication date
US20020037857A1 (en) 2002-03-28
EP1808440A1 (en) 2007-07-18
IL149042A (en) 2011-01-31
US6586405B2 (en) 2003-07-01
ES2285989T3 (es) 2007-12-01
ATE517910T1 (de) 2011-08-15
KR100879673B1 (ko) 2009-01-21
DE60034447D1 (de) 2007-05-31
DE60034447T2 (de) 2008-02-14
KR20020063562A (ko) 2002-08-03
ATE360028T1 (de) 2007-05-15
EP1182207B1 (en) 2007-04-18
EP1808440B1 (en) 2011-07-27
EP1182207A2 (en) 2002-02-27
EP1182207A3 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
ZA200202825B (en) Non-covalent inhibitors of urokinase and blood vessels formation.
WO2000005245A3 (en) Inhibitors of urokinase and blood vessel formation
WO2002014349A3 (en) Non-covalent inhibitors of urokinase and blood vessel formation
Sang et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases
GR3023537T3 (en) Inhibition of thrombin.
PH31263A (en) Methods of inhibiting vascular smooth muscle cell proliferation and restinosis.
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
ATE287715T1 (de) Verwendung von oxidosqualencyclasehemmer zur senkung des cholesterinblutspiegels
HUT75111A (en) Use of pyridyl-,oxadiazole or thiadiazole derivatives for producing pharmaceutical compositions having effect
GR3023378T3 (en) Inhibition of seborrhea and acne.
NZ264674A (en) Use of substituted benzothiophenes for inhibiting angiogenesis
DE69426855T2 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung des Knorpelabbaus
DE69226487T2 (de) Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
IL156169A0 (en) Use of 6-dimethylaminomethyl-1-phenylcyclohexane compounds for treating urinary incontinence
SI0659414T1 (en) Inhibition of hirsutism and alopecia in women